Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.

Slides:

Advertisements

Similar presentations

Triple negative breast cancer

Advertisements

Is mammacarcinoom onder de veertig jaar morfologisch en genetisch een andere ziekte? Marc van de Vijver, Netherlands Cancer Institute, Amsterdam, NL.

Figure Figure 18-1 part 1 Figure 18-1 part 2.

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Chapter 7 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.

Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.

Epidemiology. Definition Biology “Basal-Like” The “Triple Negative” Breast Cancer Estrogen Receptor (ER) negative Progesterone receptor (PR) negative.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.

Molecular subclasses of breast cancer: how do we deﬁne them? The IMPAKT 2012 Working Group Statement R4 신재령 / Prof. 김시영 Annals of Oncology 23: 2997–3006,

Case 2 A 34 year old female with a strong family history of breast cancer presented with a palpable breast mass The mass presented in the interval between.

Figure 1 The heterogenous landscape of triple-negative breast cancer

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Triple negative breast cancer 21st Annual NOCR Meeting

Figure 2. A consort diagram showing the flowchart of the trial

Hallett, et al., - Supplementary Figure 1

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

IHC-breast cancer subtypes of invasive ductal carcinoma with predominant intraductal component as an insignificant prognostic factor: A register-based.

Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001.

Figure S1. DCYTB expression is higher in ER+ than ER- patients

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

سرطان الثدي Breast Cancer

A B C Supplementary figure S7

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer Gen Wang, Xiaosong.

The immune metagene model has prognostic value in IBE but not in IBD breast cancer. The immune metagene model has prognostic value in IBE but not in IBD.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Prognostic significance of DDB2 in ovarian cancer.

Figure 1 Treatment-induced resistance and evolution to lineage crisis

Human triple‐negative breast cancers (TNBC) express WNT10B, show active Wnt signalling and have high proliferation, and WNT10B has clinical relevance and.

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

JNK signature in breast cancer cells is linked to ECM, stem cell, and wound healing gene networks and is enriched in basal‐like breast cancer JNK signature.

Volume 22, Issue 8, Pages (August 2015)

Volume 10, Issue 5, Pages (May 2018)

Overview of the complex interactions among molecular classifications of TNBC based on genomic, transcriptomic, proteomic, epigenomic, and immune characterization.

Triple‐negative human breast cancers specifically express high levels of nuclear HMGA2, whose expression has clinical relevance and predicts recurrence‐free.

FMRP is highly expressed in human breast cancer and distal metastasis FMRP expression on human TMAs containing normal and multi‐tumour tissues. FMRP is.

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

Derivation and application of cancer‐specific epithelial‐mesenchymal transition (EMT) signature A six‐step scheme illustrating the generation of a cancer‐specific.

ADAM8 is overexpressed in human breast cancer AADAM8 mRNA expression in samples from breast tumor and normal breast tissue was analyzed using the Oncomine.

Supplementary Figure S3

20-Year Risks of Breast-Cancer Recurrence

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

(A) Schematic representation of the conditional Lats2 locus.

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Correlation between Pten/p53 status and AKT pathway activity in BC and effect on clinical outcome Box plot for p53‐pathway activity in p53 wild‐type and.

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

EN1 expression in breast cancer and clinical outcome.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

ORs estimates for ER breast cancer subtypes in postmenopausal women ccording to tertiles of sex steroid hormone and SHBG levels. ORs estimates for ER breast.

MRNA expression IL-1α, IL-1β, IL-1Ra, IL-1RtI, ER α, ER β, and PR was analyzed by RT-PCR as described in “Materials and Methods.” Representative gel electrographies.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Coexpression of other immune genes with ImSig core signatures.

PD-L1 is expressed in breast cancer.

Clustering analysis of DTC-associated genes.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Molecular definitions of lung adenocarcinoma subtypes.

Identification of putative TET1 targets in TNBC

Volume 28, Issue 3, Pages e7 (July 2019)

MYC and LYN are coexpressed and have interdependent clinical outcomes.

Transcriptome traits and clinical characteristics of TME phenotypes in the ACRG cohort. Transcriptome traits and clinical characteristics of TME phenotypes.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Isolation of large soft agar clones from HBEC3p53,KRAS and HBEC3p53,KRAS,MYC identifies tumorigenic and nontumorigenic clones and genome-wide mRNA expression.

Construction of TME signatures and functional annotation.

Presentation transcript:

Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR status

Table S2: The survival events in each subgroup IBC: Inflammatory breast cancer nIBC: Non-inflammatory breast cancer OS: Overall survival DMFS: distant metastasis-free survival RFS: recurrence-free survival M: mesenchymal IM: immunomodulatory BL1: basal-like 1 BL2: basal-like 2 LAR: luminal androgen receptor UNS: unstable MSL: mesenchymal stem-like

Table S3: Patient characteristics for the 7 TNBC subtypes defined by Lehmann et al.’s signatures

Table S4: Patient characteristics for the 7 TNBC subtypes defined by our gene signatures

Table 5A: Distribution of IBC/non-IBC status by TNBC subtype using our gene signatures Table 5B: Distribution of IBC/non-IBC status by TNBC subtype using Lehmann’s gene signatures Table S5: The analysis from Table 2 with TNBC defined by IHC results instead of mRNA expression (N=63)

Figure S1A: Overall survival by subtype (IHC definition of TNBC) Figure S1B: Recurrence-free survival by subtype (IHC definition) Figure S1C: Distant metastasis-free survival by subtype (IHC definition) year

Figure S2: Box plots of AR gene expression levels in TNBC subtypes defined by our approximated gene signatures (left panel) or Lehmann’s gene signatures (right panel) Cluster defined by approximated gene signatures Cluster defined by Lehmann’s gene signatures Log intensity (batch effect removed) BL1 N=15 BL2 N=5 IM N=17 LAR N=7 M N=9 MSL N=4 UNS N=6 BL1 N=10 BL2 N=4 IM N=16 LAR N=6 M N=7 MSL N=5 UNS N=15 Figure S2: The analysis of Figure 2 with TNBC defined by IHC results instead of mRNA expression (N=63)